FAP and neoplasm: Because non-targeted tubulysin B was too toxic to administer at therapeutic concentrations 32, it was important to investigate the systemic toxicity of the FAP-targeted tubulysin B hydrazide conjugate at doses that displayed anti-tumor activity.